Open Now: The Global ETF Survey Take the Survey →

Advertisement
Advertisement

IBBvsPBEETF Comparison

ETF 1
IBB

iShares Biotechnology ETF

This fund is part of
US Health Care
+0.43%
VS
ETF 2
PBE

Invesco Dynamic Biotechnology & Genome ETF

This fund is part of
BioTech & Genomics
-0.06%

iShares Biotechnology ETF (IBB) belongs to the US Health Care segment. Invesco Dynamic Biotechnology & Genome ETF (PBE) is part of the BioTech & Genomics segment. IBB's top 3 sector exposures are Healthcare, Non-Corporate and Non-Energy Materials. In contrast, PBE's top sector exposures are Healthcare,  IBB is less expensive with a Total Expense Ratio (TER) of 0.44%, versus 0.58% for PBE. IBB is up 11.67% year-to-date (YTD) with +$98M in YTD flows. PBE performs worse with 10.5% YTD performance, and +$2M in YTD flows. Run a side-by-side ETF comparison of IBB and PBE below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.

Find out how industry players manage ETF portfolios.  Discover our library of Model portfolios

IBB vs PBE performance and flow charts

Performance

-2.0-1.00.01.02.03.04.05.0%Jun 29Jul 7Jul 14Jul 21

Cumulative Flows

-100 M0 M100 M200 M300 MJun 29Jul 7Jul 14Jul 21

Get all the metrics on this page, and more, through a reliable ETF data feed

Daily, global ETF data for advanced analysis or integration into apps (API), from our partner Trackinsight.

Historic performance and flows
Data as of 07/27/2026
1M3MYTD1Y3Y5Y
Perf.
IBB
PBE
-0.75%-0.15%
+11.49%+13.39%
+11.67%+10.50%
+40.98%+38.91%
+48.54%+46.47%
+17.67%+23.94%
Flows
IBB
PBE
+$247M+$5M
+$298M+$4M
+$98M+$2M
+$1.48B-$17M
-$917M-$51M
-$1.71B-$45M
Volatility and drawdown
3M1Y3Y5Y
Volatility
IBB
PBE
+22.57%+18.74%
+20.32%+18.86%
+20.42%+20.27%
+22.33%+22.48%
Max drawdown
IBB
PBE
-5.94%-4.30%
-9.61%-11.70%
-24.82%-22.21%
-39.75%-34.74%
Max drawdown duration
IBB
PBE
20d20d
151d166d
377d324d
1611d1540d
Trading data

Create an account to view trading data

Join for free
IBB
PBE
Last sale
7/28/2026 at 1:30 PM
$190.52
$91.74
Previous close
07/27/2026
$188.33
$89.85
Consolidated volume
07/27/2026
Average volume
30 days
Average discount or premium
30 days
Average Bid/Ask spread
30 days
Replication quality
Data as of June 30, 2026
1-year trailing difference

Create an account to view replication metrics

Join for free

Create an account to view replication quality

Join for free
IBB
PBE
Tracking error
Tracking difference
1 year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Advertisement
Main metrics
Last update 7/28/2026 at 1:30 PM
Live
Closed
IBB
PBE
Last price
$190.52
$91.74
1D performance
+1.16%
+2.10%
AuM$9.36 B$282.77 M
E/R0.44%0.58%
Characteristics
IBB
PBE
Management strategyPassivePassive
ProvideriSharesInvesco
BenchmarkICE Biotechnology IndexDynamic Biotech & Genome Intellidex Index
N° of holdings24230
Asset classEquitiesEquities
Trailing 12m distribution yield
Join
Join
Inception dateFebruary 5, 2001June 23, 2005
ESGNoNo
Advertisement
Exposure

Countries

IBB
USA
86.15%
Other
13.85%
PBE
USA
97.25%
Other
2.75%

Sectors

IBB
Healthcare
99.89%
Other
0.11%
PBE
Healthcare
100%
Other
-0%

Diversification

IBB

Total weight of top 15 holdings out of 15

53.71%
PBE

Total weight of top 15 holdings out of 15

60.29%

Top 15 holdings

Data as of June 30, 2026
IBB
Vertex Pharmaceuticals, Inc.
8.07%
Amgen, Inc.
7.82%
Gilead Sciences, Inc.
6.83%
Regeneron Pharmaceuticals, Inc.
4.90%
argenx SE
3.75%
Alnylam Pharmaceuticals, Inc.
3.12%
Natera, Inc.
2.89%
Revolution Medicines, Inc.
2.78%
Biogen, Inc.
2.46%
Illumina, Inc.
2.07%
Moderna, Inc.
1.98%
Insmed, Inc.
1.78%
BeOne Medicines Ltd.
1.77%
Incyte Corp.
1.75%
United Therapeutics Corp.
1.73%
PBE
Vertex Pharmaceuticals, Inc.
5.12%
Biogen, Inc.
5.08%
Amgen, Inc.
4.84%
Royalty Pharma Plc
4.74%
Regeneron Pharmaceuticals, Inc.
4.53%
Alnylam Pharmaceuticals, Inc.
4.48%
Gilead Sciences, Inc.
4.34%
United Therapeutics Corp.
4.26%
Bio-Techne Corp.
3.67%
Veracyte, Inc.
3.39%
CareDx, Inc.
3.31%
Vericel Corp.
3.27%
Repligen Corp.
3.16%
PTC Therapeutics, Inc.
3.09%
Protagonist Therapeutics, Inc.
3.02%
Frequently asked questions about IBB and PBE

How have the IBB and PBE ETFs performed in 2026?

As of July 27, 2026, IBB is up 11.67% year-to-date (YTD), while PBE has returned 10.5%. That puts IBB better performer ahead so far this year.

Which ETF is attracting more investor money: IBB or PBE?

Year-to-date, the IBB ETF saw +$98M in flows, compared to +$2M for PBE.

Which ETF is more volatile: IBB or PBE?

Over the past year, IBB had a volatility of 20.32%, while PBE experienced 18.86%.

Which ETF is bigger: IBB or PBE?

As of July 27, 2026, IBB holds $9.36 B in assets under management (AUM), while PBE manages $282.77 M.

What sectors do the IBB and PBE ETFs invest in?

IBB leans toward sectors like Healthcare. Meanwhile, PBE focuses on Healthcare.

What are the top holdings of the IBB ETF and PBE ETF?

IBB top holdings include Vertex Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.. PBE holds in its top three: Vertex Pharmaceuticals, Inc., Biogen, Inc. and Amgen, Inc..

Which ETF is more diversified: IBB or PBE?

IBB holds 242 securities with 53.71% of its assets in the top 15. PBE has 30 securities and a top 15 weight of 60.29%.

Advertisement
Advertisement
Advertisement
Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey and get exclusive early access to the final report.

Global ETF Survey 2026